Silence Therapeutics PLC (SLN) ニュース

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form DEL AM - Delaying amendment

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to...

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp(a) after single and multiple dosing Silence...

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Silence also announced positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high lipoprotein(a) Company to...

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Study met primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36 Lipoprotein(a) reduction was consistent with phase...

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to...

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Curtis Rambaran, MD, promoted to Chief Medical Officer Marie Wikström Lindholm, PhD, promoted to Chief...